The mucosal immune system for vaccine development |
| |
Authors: | Aayam Lamichhane Tatsuhiko Azegami Hiroshi Kiyono |
| |
Affiliation: | 1. Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan;2. International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan;3. Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan |
| |
Abstract: | Mucosal surfaces are continuously exposed to the external environment and therefore represent the largest lymphoid organ of the body. In the mucosal immune system, gut-associated lymphoid tissues (GALTs), including Peyer's patches and isolated lymphoid follicles, play an important role in the induction of antigen-specific immune responses in the gut. GALTs have unique organogenesis characteristics and interact with the network of dendritic cells and T cells for the simultaneous induction and regulation of IgA responses and oral tolerance. In these lymphoid tissues, antigens are up taken by M cells in the epithelial layer, and antigen-specific immune responses are subsequently initiated by GALT cells. Nasopharynx- and tear-duct-associated lymphoid tissues (NALTs and TALTs) are key organized lymphoid structures in the respiratory tract and ocular cavities, respectively, and have been shown to interact with each other. Mucosal surfaces are also characterized by host-microbe interactions that affect the genesis and maturation of mucosa-associated lymphoid tissues and the induction and regulation of innate and acquired mucosal immune responses. Because most harmful pathogens enter the body through mucosal surfaces by ingestion, inhalation, or sexual contact, the mucosa is a candidate site for vaccination. Mucosal vaccination has some physiological and practical advantages, such as decreased costs and reduced risk of needle-stick injuries and transmission of bloodborne diseases, and it is painless. Recently, the application of modern bioengineering and biochemical engineering technologies, including gene transformation and manipulation systems, resulted in the development of systems to express vaccine antigens in transgenic plants and nanogels, which will usher in a new era of delivery systems for mucosal vaccine antigens. In this review, based on some of our research group's thirty seven years of progress and effort, we highlight the unique features of mucosal immune systems and the application of mucosal immunity to the development of a new generation of vaccines. |
| |
Keywords: | APC, antigen presenting cell cCHP, cationic type of cholesteryl group-bearing pullulan CCL, CC chemokine ligand CCR, CC chemokine receptor CMIS, common mucosal immune system CT, cholera toxin CTB, cholera enterotoxin B subunit CXCL, CXC chemokine ligand CXCR, CXC chemokine receptor DC, dendritic cell Ig, immunoglobulin IgA+ B cell, IgA-committed B cell FAE, follicle-associated epithelium GALT, gut-associated lymphoid tissue GI, gastrointestinal gp2, glycoprotein 2 Id2, inhibitor of DNA binding 2 IL, Interleukin ILF, isolated lymphoid follicle LP, lamina propria LPS, lipopolysaccharide LT, heat-labile enterotoxin LTB, heat-labile enterotoxin B subunit MALT, mucosa-associated lymphoid tissue M cell, microfold/membranous cell NALT, nasopharynx-associated lymphoid tissue PP, Peyer's patch PspA, pneumococcal surface protein A RANKL, receptor activator of nuclear factor κB ligand RORγt, retinoic-acid-receptor-related orphan receptor-γ SIgA, secretory immunoglobulin A TALT, tear duct-associated lymphoid tissue TGF, transforming growth factor Th, T helper TLR, toll-like receptor TNFR, tumor necrosis factor receptor Treg, regulatory T UEA-1, ulex europaeus agglutinin 1 |
本文献已被 ScienceDirect 等数据库收录! |
|